242 related articles for article (PubMed ID: 16927371)
1. Mobilization of Ph chromosome-negative peripheral blood stem cells in a child with chronic myeloid leukemia after imatinib-induced complete molecular remission.
Woods-Swafford W; Vnencak-Jones CL; Loken MR; Manes B; Frangoul H
Pediatr Blood Cancer; 2008 Mar; 50(3):639-41. PubMed ID: 16927371
[TBL] [Abstract][Full Text] [Related]
2. Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease.
DeAngelo DJ; Hochberg EP; Alyea EP; Longtine J; Lee S; Galinsky I; Parekkedon B; Ritz J; Antin JH; Stone RM; Soiffer RJ
Clin Cancer Res; 2004 Aug; 10(15):5065-71. PubMed ID: 15297408
[TBL] [Abstract][Full Text] [Related]
3. A comparison of donor lymphocyte infusions or imatinib mesylate for patients with chronic myelogenous leukemia who have relapsed after allogeneic stem cell transplantation.
Weisser M; Tischer J; Schnittger S; Schoch C; Ledderose G; Kolb HJ
Haematologica; 2006 May; 91(5):663-6. PubMed ID: 16627251
[TBL] [Abstract][Full Text] [Related]
4. BCR/ABL-negative clonogenic hematopoietic cells do not accumulate in the plastic-adherent fraction of peripheral blood mononuclear cells from patients with chronic myeloid leukemia in stable chronic phase.
Schultheis B; Pasternak G; Hehlmann R
Folia Biol (Praha); 2000; 46(6):256-63. PubMed ID: 11140859
[TBL] [Abstract][Full Text] [Related]
5. Peripheral blood progenitor cell collection in chronic myeloid leukemia patients with complete cytogenetic response after treatment with imatinib mesylate.
Perseghin P; Gambacorti-Passerini C; Tornaghi L; Dassi M; Pioltelli P; Parma M; Colnaghi F; Giudici G; Elli E; Fumagalli M; Ponchio L; Biondi A; Pogliani EM
Transfusion; 2005 Jul; 45(7):1214-20. PubMed ID: 15987369
[TBL] [Abstract][Full Text] [Related]
6. Collection of Philadelphia-negative stem cells using recombinant human granulocyte colony-stimulating factor in chronic myeloid leukemia patients treated with alpha-interferon.
Hernández-Boluda JC; Carreras E; Cervantes F; Marín P; Arellano-Rodrigo E; Rovira M; Solé F; Lloveras E; Espinet B; Ocejo A; Montserrat E
Haematologica; 2002 Jan; 87(1):17-22. PubMed ID: 11801461
[TBL] [Abstract][Full Text] [Related]
7. Successful peripheral blood stem cell mobilisation with filgrastim in patients with chronic myeloid leukaemia achieving complete cytogenetic response with imatinib, without increasing disease burden as measured by quantitative real-time PCR.
Hui CH; Goh KY; White D; Branford S; Grigg A; Seymour JF; Kwan YL; Walsh S; Hoyt R; Trickett A; Rudzki B; Ma DD; To LB; Hughes TP
Leukemia; 2003 May; 17(5):821-8. PubMed ID: 12750692
[TBL] [Abstract][Full Text] [Related]
8. Hematological and molecular response evaluation of CML patients on imatinib.
Gupta A; Prasad K
J Assoc Physicians India; 2007 Feb; 55():109-13. PubMed ID: 17571739
[TBL] [Abstract][Full Text] [Related]
9. [Imatinib therapy for patients with chronic myelogenous leukemia].
Usui N
Gan To Kagaku Ryoho; 2005 Mar; 32(3):297-303. PubMed ID: 15791812
[TBL] [Abstract][Full Text] [Related]
10. [Autogeneic peripheral blood hemopoietic stem cell transplantation for chronic myeloid leukemia with imatinib mesylate-induced negative Philadelphia chromosome].
Meng FY; Sun J; Liu QF; Xu D; Yang LJ; Song LL; Liu XL; Xu B; Zhou SY
Di Yi Jun Yi Da Xue Xue Bao; 2003 Dec; 23(12):1301-2, 1306. PubMed ID: 14678896
[TBL] [Abstract][Full Text] [Related]
11. Early allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era: a preliminary assessment.
Simon W; Segel GB; Lichtman MA
Blood Cells Mol Dis; 2006; 37(2):116-24; discussion 125-7. PubMed ID: 16904348
[TBL] [Abstract][Full Text] [Related]
12. [Successful attainment of the third chronic phase by autologous peripheral blood stem cell transplantation and imatinib in a patient with chronic myeloid leukemia].
Tabata S; Ohno T; Tomo K; Hishita T; Hada S; Mizumoto T; Furukawa H
Rinsho Ketsueki; 2003 May; 44(5):313-7. PubMed ID: 12822405
[TBL] [Abstract][Full Text] [Related]
13. Durable molecular response to imatinib mesylate following nonmyeloablative allogeneic stem-cell transplantation for persisting myeloid blast crisis in chronic myeloid leukemia.
Staber PB; Brezinschek R; Linkesch W; Sill H; Neumeister P
Haematologica; 2003 Aug; 88(8):ECR29. PubMed ID: 12935988
[TBL] [Abstract][Full Text] [Related]
14. Autologous stem cell transplantation in chronic myeloid leukemia.
Olavarria E
Semin Hematol; 2007 Oct; 44(4):252-8. PubMed ID: 17961724
[TBL] [Abstract][Full Text] [Related]
15. Sustained clinical remission despite suboptimal molecular response to imatinib in e1a2 BCR-ABL chronic myeloid leukemia.
Langabeer SE; Crampe M; Haslam K; Kelly J; Cahill MR
Leuk Res; 2010 Jul; 34(7):e176-7. PubMed ID: 20153526
[No Abstract] [Full Text] [Related]
16. Imatinib-related bone marrow aplasia after complete cytogenetic response in chronic myeloid leukemia.
Khan KA; Junaid A; Siddiqui NS; Mukhtar K; Siddiqui S
J Coll Physicians Surg Pak; 2008 Mar; 18(3):176-8. PubMed ID: 18460249
[TBL] [Abstract][Full Text] [Related]
17. Long-term remission with imatinib mesylate in Philadelphia chromosome-positive AML presenting as primary extramedullary myeloid sarcoma.
Ahmed MS; Kroft SH; Davis NB; King DM; Cheng YC
Leuk Res; 2008 Sep; 32(9):1476-9. PubMed ID: 18308388
[TBL] [Abstract][Full Text] [Related]
18. Optimizing therapy of chronic myeloid leukemia.
Deininger MW
Exp Hematol; 2007 Apr; 35(4 Suppl 1):144-54. PubMed ID: 17379100
[TBL] [Abstract][Full Text] [Related]
19. Initial treatment for patients with CML.
Goldman JM
Hematology Am Soc Hematol Educ Program; 2009; ():453-60. PubMed ID: 20008231
[TBL] [Abstract][Full Text] [Related]
20. Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells.
Jiang X; Saw KM; Eaves A; Eaves C
J Natl Cancer Inst; 2007 May; 99(9):680-93. PubMed ID: 17470736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]